A Multi-center, Randomized, Double-blind, Placebo-controlled Phase IIa Trial to Compare the Safety of ABX464 Given at a Fixed Dose to Placebo in Fully Controlled HIV Infected Patients Treated With Boosted Protease Inhibitor Treatment (Darunavir/Ritonavir or Darunavir/Cobicistat).
Phase of Trial: Phase II
Latest Information Update: 27 Sep 2017
At a glance
- Drugs ABX 464 (Primary)
- Indications HIV infections
- Focus Adverse reactions
- Sponsors Abivax
- 26 Jul 2017 Results presented at the 9th International AIDS Society Conference on HIV Science.
- 19 Jun 2017 Status changed from recruiting to completed.
- 23 May 2017 Planned primary completion date changed from 1 Dec 2016 to 1 May 2017.